Europe
Investigating a new marker for chronic inflammation GlycA, researchers have found that chronic inflammation is linked to increased risk for shorter lifespan and several organ-related diseases. The findings were made through investigating GlycA measurements with Nightingale Health’s blood testing technology. The results highlight a potential use for measuring GlycA in healthcare.
Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Clinigen Group plc announces that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.
Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.
New research published in The Journal of Physiology presents a breakthrough in the treatment of Restless Legs Syndrome (RLS).
A substantial new documentary film released online to audiences in the UK and across Europe this week, questions claims made by UK, Danish and Spanish health authorities that widespread administering of the HPV vaccine is both safe and a guaranteed means of preventing cervical cancer.
Biomimicry, looking at how things are done in nature and applying that to solve problems, is utilized by many researchers. BioSpace looks at some examples of how scientists are performing cutting-edge research using biomimicry.
In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
Since taking over as chief executive officer of Swiss pharma giant Novartis, Vas Narasimhan has been actively reshaping the company to focus on therapies that will drive revenue well into the future.
Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.
PRESS RELEASES